As filed with the Securities and Exchange Commission on June 19, 2015
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
For Registration of Certain Classes of Securities
Pursuant to Section 12(b) or 12(g) of
the Securities Exchange Act of 1934
PROVECTUS BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 90-0031917 | |
(State of incorporation or organization) | (I.R.S. Employer Identification No.) | |
7327 Oak Ridge Highway Suite A Knoxville, Tennessee |
37931 | |
(Address of principal executive offices) | (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class to be so registered |
Name of each exchange on which each class is to be registered | |
Warrants, exercisable for one share of common stock, par value $0.001 per share, at an exercise price of $0.85 per share |
NYSE MKT LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. x
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ¨
Securities Act registration statement file number to which this form relates: 333-182476
Securities to be registered pursuant to Section 12(g) of the Act: None
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Item 1. | Description of Registrants Securities to be Registered. |
For a description of the securities of Provectus Biopharmaceuticals, Inc. (the Registrant) being registered hereunder, reference is made to the information set forth under (i) the heading Description of Warrants contained in the Registrants Registration Statement on Form S-3 (File No. 333-182476), as initially filed with the Securities and Exchange Commission (the SEC) on July 2, 2012, as amended (the Registration Statement), and (ii) in the heading Description of SecuritiesWarrants in the preliminary prospectus supplement, included in the Registration Statement and filed separately by the Registrant with the SEC on June 19, 2015, as the same may be amended or supplemented from time to time, in each case pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which information shall be deemed to be incorporated by reference herein.
Item 2. | Exhibits. |
The following exhibits are hereby incorporated by reference herein:
Exhibit |
Description | |
3.1 | Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrants annual report on Form 10-K filed with the SEC on March 13, 2014). | |
3.2 | Certificate of Amendment to the Registrants Certificate of Incorporation (incorporated by reference to Exhibit 3.2 of the Registrants annual report on Form 10-K filed with the SEC on March 12, 2015). | |
3.3 | Bylaws of the Registrant (incorporated by reference to Exhibit 3.4 of the Companys annual report on Form 10-K filed with the SEC on March 13, 2014). | |
4.1 | Form of Warrant Agency Agreement among the Registrant and Broadridge Corporate Issuer Solutions, Inc. (incorporated by reference to Exhibit 4.1 of the Registrants Current Report on Form 8-K filed with the SEC on June 19, 2015). | |
4.2 | Form of Warrant Certificate (incorporated by reference to Exhibit 4.2 of the Registrants Current Report on Form 8-K filed with the SEC on June 19, 2015). |
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
Date: June 19, 2015
PROVECTUS BIOPHARMACEUTICALS, INC. | ||
By: | /s/ Peter R. Culpepper | |
Name: | Peter R. Culpepper | |
Title: | Chief Financial Officer & Chief Operating Officer |